Features associated with the development of hallucinations in Parkinson's disease


Creative Commons License

Benbir G. , Ozekmekci S., Cinar M., Beskardes F., Apaydin H. , Erginoz E.

ACTA NEUROLOGICA SCANDINAVICA, vol.114, no.4, pp.239-243, 2006 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 114 Issue: 4
  • Publication Date: 2006
  • Doi Number: 10.1111/j.1600-0404.2006.00644.x
  • Title of Journal : ACTA NEUROLOGICA SCANDINAVICA
  • Page Numbers: pp.239-243

Abstract

Objective – To identify features related to the development of

hallucinations in Parkinson’s disease (PD). Materials and methods –

Seventy PD patients with hallucinations (group 1) and 60 PD patients

without hallucinations (group 2) were evaluated for disease severity,

presence of motor complications, rapid eye movement (REM) behavior

disorder (RBD), and antiparkinsonian drug profile. The ages at the

emergence of hallucinations and duration of disease in group 1 were

matched with the ages at the last visit of those in group 2.

Results – Disease severity and presence of motor complications were similar in both

groups. RBD was more frequently encountered among hallucinators

thanamongnon-hallucinators. The mean duration and daily

doses of levodopa and other dopaminergic drugs did not differ in both

groups; however, the usage of anticholinergics and amantadine were

significantly more frequent in group 2, unexpectedly.

Conclusions – The presence of RBD was significantly more common in hallucinators;

however,severityofPD,duration and

daily doses of dopaminergic drugs

were not associated with the emergence of hallucinations

Objective - To identify features related to the development of hallucinations in Parkinson's disease (PD). Materials and methods - Seventy PD patients with hallucinations (group 1) and 60 PD patients without hallucinations (group 2) were evaluated for disease severity, presence of motor complications, rapid eye movement (REM) behavior disorder (RBD), and antiparkinsonian drug profile. The ages at the emergence of hallucinations and duration of disease in group 1 were matched with the ages at the last visit of those in group 2. Results - Disease severity and presence of motor complications were similar in both groups. RBD was more frequently encountered among hallucinators than among non-hallucinators (P = 0.007). The mean duration and daily doses of levodopa and other dopaminergic drugs did not differ in both groups; however, the usage of anticholinergics and amantadine were significantly more frequent in group 2, unexpectedly. Conclusions - The presence of RBD was significantly more common in hallucinators; however, severity of PD, duration and daily doses of dopaminergic drugs were not associated with the emergence of hallucinations.